Dr Josep Torrent-Farnell | Medicines Department
Catalan Health Service

Dr Josep Torrent-Farnell, Medicines Department, Catalan Health Service

Dr. Josep Torrent-Farnell. PhD in Medicine and Surgery and Bachelor of Pharmacy, specialist in internal medicine and clinical pharmacology. Head of the medicine division of the CatSalut, of the Generalitat de Catalunya (May 2016). Full Professor of the Department of Clinical and Therapeutic Pharmacology of the Universitat Autònoma de Barcelona and Head of Section of the Pharmacology Service of the Santa Creu i Sant Pau Hospital. First elected President (2000-2007) and member of the Committee for Orphan Medicinal Products and the Scientific Advisory Committee of the European Agency (2009-2012), member of the Rare Diseases Task Force. EURORDIS expert on research and training programs. He also was a Public Health Executive Agency for the European Union (2006-2010). Expert in the National Strategy for Rare Diseases (2007-2012), member of the Advisory Committee on Minority Diseases (CAMM) and chair of the High Complexity Pharmacological Treatment Advisory Council, Catalan Health Service (2010-2016). Chairman of the Scientific Committee of the CIBER Rare Diseases, President of the Therapies Scientific Committee of the International Rare Diseases Research Consortium (IRDiRC). He is an expert from the Conseil Scientifique de l'Agence Nationale de Sécurité du Médecament et des Produits de Santé de France (since 2011). Member of the Ethics Committee of Farmaindustria. Coordinator for the creation and first executive director of the Spanish Medicines Agency (1998-2000) and Head of the innovative drugs sector of the European Agency (1994-1998). Order of the Civil Order of the Ministry of Health (2009). Special distinction of the Association of Patients of Rare Diseases of the United States (NORD, 2005). Special Distinction to Leadership in Rare Diseases in Europe by the European Federation of Rare Disease Patients (EURORDIS, 2015).


Day 2, Nov 8 @ 09:25

Speaking from experience, expedited regulatory pathways in gaining EMA PRIME examples – Where do we go from there?

  • Paving the way for biotechs to gain approval and access
  • Recent changes and future amendments to regulatory issues surrounding orphan drugs approval
  • How are companies interacting the payers and how to close the gap to allow treatments to reach patients
Discussion with payer and PRIME designated companies
last published: 04/Nov/18 13:45 GMT

back to speakers

Follow us on


Sign Up for Event Updates

Get Involved At World Orphan Drug Congress 2018


To Sponsor Or Exhibit


Andrew Mears
t/ +44 20 7092 1228


To Speak


Wing-Yun Cheung
t/ +44 20 7092 1172


To Register


Issa Mauthoor
t/ +44 20 7092 1257